Participated · Series C · Oct 2025

Hemab Therapeutics is focused on creating prophylactic, antibody-based treatments that address the underlying causes of serious bleeding disorders rather than just managing acute events. Its lead asset, sutacimig (formerly HMB-001), has completed Phase 2 in Glanzmann thrombasthenia and is being prepared for a registration study in 2026, with a parallel Phase 2 program planned for Factor VII deficiency. The company’s second clinical candidate, HMB-002, targets the C-terminal CK domain of Von Willebrand Factor to raise endogenous VWF and Factor VIII levels and is advancing toward registration studies in Von Willebrand disease. Backed by its “Hemab 1-2-5” strategy, the team is also moving additional programs forward, with HMB-003 expected to enter the clinic in the first half of 2026. Hemab’s dual headquarters in Cambridge, Massachusetts, and Copenhagen, Denmark, give it access to both U.S. and European scientific ecosystems. The fresh Series C financing provides $157 million to fund late-stage trials, expand the pipeline, and reinforce the company’s goal of becoming “the ultimate clotting company.”

Led · Series A · Jun 2025

Draig Therapeutics is a clinical-stage biopharma focused on developing highly specific AMPA receptor (AMPAR) and GABAA receptor (GABAAR) modulators aimed at treating neuropsychiatric disorders. Its lead program, DT-101, is a Phase 2 AMPAR positive allosteric modulator (PAM) being evaluated in major depressive disorder in a global monotherapy study and a U.S. adjunct study. The company states DT-101 has shown encouraging safety, tolerability and target engagement with a pulsatile pharmacokinetic profile. Draig was co-founded by Cardiff University and SV Health Investors and is backed by venture investors including Access Biotechnology, Canaan Partners, SR One, Sanofi Ventures and Schroders Capital. Following the oversubscribed $65 million Series B, the company plans to use proceeds to accelerate clinical development across its pipeline and advance additional candidates toward the clinic.

Participated · Series B · Mar 2025

Latigo Biotherapeutics is a clinical-stage biotech focused on developing best-in-class non-opioid pain medicines that target pain at its source via selective Nav1.8 inhibition. Its lead candidate, LTG-001, is an oral selective Nav1.8 inhibitor for acute pain and reported positive Phase 1 first-in-human results, showing it was well tolerated with rapid absorption. A second oral Nav1.8 inhibitor, LTG-305, is in Phase 1 trials aimed at chronic pain and is being evaluated for safety, tolerability, and pharmacokinetics. The company’s stated goal is to provide effective, rapid-acting pain relief without the risk of addiction. Latigo recently closed a $150 million Series B to support advancement of its Nav1.8 clinical programs and the development of a broader pipeline. The company is based in Thousand Oaks, Calif. Latigo Biotherapeutics is a Thousand Oaks, CA-based clinical-stage biotech focused on non-opioid pain therapeutics that act on the fundamental mechanism of pain transduction. The company uses proprietary in-house technology that applies AI, machine learning, structure-based, and knowledge-based design to generate drugs against targets validated by human genetics. Its lead program, LTG-001, is an oral, selective Nav1.8 inhibitor currently in a Phase 1 clinical trial in healthy volunteers intended to treat acute and chronic pain. Latigo also maintains a suite of Nav1.8 inhibitors to address the broader clinical potential of the target and has additional small-molecule discovery programs against genetically identified targets. Leadership changes accompanying the financing include the appointment of Desmond Padhi as interim CEO and Nancy Stagliano as chair of the board. The company intends to use the proceeds to support continued advancement of its portfolio of novel pain therapeutics.

Participated · Series B · Aug 2024

Halda Therapeutics is advancing a proprietary RIPTAC™ modality, a heterobifunctional "hold and kill" approach that brings together a cancer-specific protein and an essential protein to selectively kill cancer cells. The company’s lead candidate, HLD-0915, is expected to enter a Phase 1 clinical trial in the first half of 2025 for metastatic, castration-resistant prostate cancer (mCRPC). Halda is also advancing a second RIPTAC program toward clinical development in metastatic breast cancer. Proceeds from the recent financing will support these IND-enabling and early clinical activities, help build the team, and fund additional RIPTAC programs for other indications. The company was founded by Professor Craig Crews of Yale and is located in New Haven, CT. Including the new financing, Halda has raised $202 million to date.

Led · Series B · Jul 2024

GRO Biosciences leverages synthetic biology to expand the amino acid alphabet and develop protein therapeutics bearing non-standard amino acids (NSAAs). Its lead program, ProGly-Uricase, is being developed to treat severe, refractory gout by preventing anti-drug antibody (ADA) formation and maintaining long-term control of serum uric acid. The company’s ProGly NSAAs contain glycans designed to educate the immune system to tolerate therapeutic proteins, a mechanism the company says is extensible to other immunogenic therapies and autoimmune indications. GRObio is also developing therapies that aim to confer antigen-specific tolerance without broad immunosuppression. Proceeds from the recent financing will advance the lead program into the clinic, broaden the internal pipeline, and expand the genomically recoded organism (GRO) platform for scalable production of proteins with multiple NSAAs. The company is headquartered in Cambridge, MA and has raised more than $90 million in total capital to date. GRO Biosciences leverages its proprietary GRO platform to expand the amino-acid alphabet and manufacture proteins containing non-standard amino acids (NSAAs) using production organisms with modified genomes and engineered translational machinery. The company pairs computational protein design, robotics, strain and genome engineering, and analytics in a differentiated biofoundry to accelerate discovery and scale NSAA protein production. GRObio is advancing two initial NSAA chemistry families: DuraLogic™, which focuses on enhanced therapeutic stability and dosing, and ProGly™, which comprises glycan-containing NSAAs to modulate immune responses. The company is targeting autoimmune and metabolic diseases and plans to pursue strategic partnerships while advancing internally developed programs. GRObio recently closed a $25 million Series A financing (part of $31.2 million total investment with earlier investors) to support further platform development, bioprocess scale-up, preclinical validation and IND-enabling studies. The GRO platform is presented as enabling previously inaccessible chemistries and scalable NSAA protein “factories” for novel biologic capabilities. GRO Biosciences is a Boston-based company developing genomically recoded organisms to express therapeutic proteins. It leverages computational protein design and synthetic biology to create protein therapeutics with enhanced properties such as increased potency, stability, and improved targeting and delivery into cells and tissues. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into protein therapeutics aimed at diabetes, growth disorders and autoimmunity. GRO intends to use its recently raised seed funding to build out bioprocess development for this platform. The financing will support development and scale-up of therapeutics that exploit non-standard amino acid incorporation for improved performance. The company’s scientific leadership and advisors include CEO Daniel J. Mandell, CSO Christopher J. Gregg, principal scientist P. Benjamin Stranges, and advisors George M. Church, Andrew D. Ellington, Marc J. Lajoie, and Ross Thyer.